Development of the Rat Model of Lapatinib-Induced Diarrhoea

Table 1

Diarrhoea associated with FDA approved TKIs targeting EGFR.

Drug	Target	All grade diarrhoea	Grade 3/4 diarrhoea	Reference
Erlotinib (Tarceva)	EGFR	62–76%	3–10%	[8]
Gefitinib (Iressa)	EGFR	57–67%	12–13%	[8]
Lapatinib (Tykerb)	EGFR, HER2	50%	6%	[12]
Vandetanib (Caprelsa)	EGFR, VEGFR	56–67%	10%	[13, 14]
Afatinib (Gilotrif)	EGFR, HER2, and ErbB4	78%	14%	[8]